Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This is a single site, prospective, randomized, double-blind study of a single intravenous autologous or allogeneic, unrelated cord blood (CB) infusion in children ages 2-7 years with Autism Spectrum Disorder (ASD). Participants will be randomly assigned to Sequence A, consisting of a single infusion of CB cells at baseline followed 6 months later by a single infusion of placebo, or Sequence B, consisting of an infusion of placebo at baseline followed 6 months later by an infusion of CB cells. All participants will ultimately be treated with CB cells at some point during the study. Participants with an available qualified autologous CB unit will receive autologous cells, and those without a suitable autologous CB unit available will receive cells from a ≥4/6 HLA-matched, ABO-matched allogeneic, unrelated donor CB unit from the Carolinas Cord Blood Bank. All infusions will be double-blinded. The primary outcomes will be assessed 6 months after the initial infusion in the sequence. Additional testing for secondary exploratory analyses will be performed at 12 months. Duration of study participation will be 12 months from the time of baseline infusion.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cord Blood Infusion (best source) | Experimental | Subjects will be randomized to receive a cord blood infusion at the baseline or 6 month visit. The cord blood will be autologous (if available) or unrelated cord blood. |
|
| Placebo Infusion | Placebo Comparator | Subjects will be randomized to receive a placebo infusion at the baseline or 6 month visit. The placebo is an acellular media product similar in both appearance and odor. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cord Blood Infusion | Biological |
| ||
| Placebo |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Social Communication as Measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3) | The Vineland Adaptive Behavior Scales, Third Edition (VABS-3) Socialization domain standard score has mean=100 and standard deviation=15 (range: 20-140). Higher scores indicate better developed adaptive social behavior. The change in the Socialization domain standard score was calculated for each participant from Baseline to Month 6. Changes in the Socialization standard score are indicative of skill acquisition relative to chronologically aged peers of the same sex. Thus, a zero (no change) represents change consistent with what is expected. An increase represents acquisition of more skills over time than would be expected. Participants who experience a decrease in Socialization standard score may still have acquired skills although not at the rate expected based on their age and sex. | Baseline, 6 months |
| Measure | Description | Time Frame |
|---|---|---|
| Change in Vineland Socialization Domain Raw Score | There are 3 raw scores within the Socialization domain of the VABS-3. These are the Interpersonal Relationships Raw Score (range: 0-86), the Play and Leisure Raw Score (range: 0-72), and the Coping Skills Raw Score (range: 0-66). Higher numbers on all three scores reflect better functioning in each area. Each raw score is the sum of the item scores in the respective subdomain of Socialization skills. The items are scored as follows: 2=usually present, 1=sometimes present, 0= never present. The item scores are assigned by a trained interviewer who interviews the parent of the child participating in the study. The change in raw score was calculated for each participant from Baseline to Month 6. Positive scores indicate improvement over time whereas negative scores indicate worsening, and zero indicates no change. The scores are not norm-referenced. |
Not provided
Inclusion Criteria:
Age ≥ 2 years to ≤ 7 years (7 years, 364 days) at the time of visit 1
Confirmed clinical DSM-5 diagnosis of Autism Spectrum Disorder using the DSM-5 Checklist
Fragile X testing performed and negative
Available and qualified umbilical cord blood unit with a minimum banked total nucleated cell dose of ≥ 2.5 x 107 cells/kg that meets criteria outlined in Section 6.0, either:
Stable on current psychiatric medication regimen (dose and dosing schedule) for at least 2 months prior to infusion of study product
Normal absolute lymphocyte count (≥1500/uL)
Participant and parent/guardian are English speaking
Able to travel to Duke University two times (baseline and 6 months post-baseline), and parent/guardian is able to participate in interim surveys and interviews
Parental consent
Exclusion Criteria:
General:
Genetic:
Infectious:
Medical:
Current/Prior Therapy:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Joanne Kurtzberg, MD | Duke Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27705 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 37151032 | Derived | Yuan A, Sabatos-DeVito M, Bey AL, Major S, Carpenter KL, Franz L, Howard J, Vermeer S, Simmons R, Troy J, Dawson G. Automated movement tracking of young autistic children during free play is correlated with clinical features associated with autism. Autism. 2023 Nov;27(8):2530-2541. doi: 10.1177/13623613231169546. Epub 2023 May 8. | |
| 36353577 |
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cord Blood Infusion, Then Placebo Infusion | Subjects will be randomized to receive a cord blood infusion at the baseline visit, followed by a placebo infusion at 6 months. The cord blood will be autologous (if available) or unrelated cord blood. The placebo is an acellular media product similar in both appearance and odor. Cord Blood Infusion Placebo |
| FG001 | Placebo Infusion, Then Cord Blood Infusion | Subjects will be randomized to receive a placebo infusion at the baseline visit, followed by a cord blood infusion at 6 months. The placebo is an acellular media product similar in both appearance and odor. The cord blood will be autologous (if available) or unrelated cord blood. Cord Blood Infusion Placebo |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
The protocol-specified pilot subjects, both randomized to placebo, were also mistakenly enrolled several days after their 8th birthday, in violation of the age-related inclusion criteria.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cord Blood Infusion, Then Placebo Infusion | Subjects will be randomized to receive a cord blood infusion at the baseline visit, followed by a placebo infusion at 6 months. The cord blood will be autologous (if available) or unrelated cord blood. The placebo is an acellular media product similar in both appearance and odor. Cord Blood Infusion Placebo |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Median |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Change in Social Communication as Measured by the Vineland Adaptive Behavior Scales, Third Edition (VABS-3) | The Vineland Adaptive Behavior Scales, Third Edition (VABS-3) Socialization domain standard score has mean=100 and standard deviation=15 (range: 20-140). Higher scores indicate better developed adaptive social behavior. The change in the Socialization domain standard score was calculated for each participant from Baseline to Month 6. Changes in the Socialization standard score are indicative of skill acquisition relative to chronologically aged peers of the same sex. Thus, a zero (no change) represents change consistent with what is expected. An increase represents acquisition of more skills over time than would be expected. Participants who experience a decrease in Socialization standard score may still have acquired skills although not at the rate expected based on their age and sex. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
6 months and 12 months
Adverse events collected on Safety Population (all 180 participants). Participants were randomized to receive a single infusion of umbilical cord blood or placebo and evaluated at six months. Participants then received a second infusion in a blinded fashion (placebo for participants initially randomized to cord blood, and cord blood for participants initially randomized to placebo). Participants were then followed for an additional 6 months for safety data collection.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cord Blood Infusion - 6 Months | Subjects will be randomized to receive a cord blood infusion at the baseline visit. The cord blood will be autologous (if available) or unrelated cord blood. Cord Blood Infusion |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Gastroenteritis | Infections and infestations | MedDRA | Non-systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Gait disturbance | General disorders | MedDRA | Non-systematic Assessment |
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Jesse D. Troy, PhD, MPH | Duke University | 919-668-1102 | cordbloodtherapyinfo@dm.duke.edu |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot_SAP | Yes | Yes | No | Study Protocol and Statistical Analysis Plan | Mar 15, 2018 | Aug 12, 2019 | Prot_SAP_000.pdf |
Not provided
| ID | Term |
|---|---|
| D000067877 | Autism Spectrum Disorder |
| D001321 | Autistic Disorder |
| ID | Term |
|---|---|
| D002659 | Child Development Disorders, Pervasive |
| D065886 | Neurodevelopmental Disorders |
| D001523 | Mental Disorders |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Biological |
|
| Baseline, 6 months |
| Change in Vineland Socialization Domain Age Equivalent | There are 3 age equivalent scores within the Socialization domain of the VABS-3: the Interpersonal Relationships Age Equivalent, the Play and Leisure Age Equivalent, and the Coping Sills Age Equivalent. An individual participant's age equivalent represents the chronological age (in years:months) at which their score would be considered normative. The age equivalent ranges are 0:0-22:0, 0:0-20:0, and 2:0-22:0 for the Interpersonal Relationships, Play and Leisure and Coping Skills age equivalents, respectively. The change in this age equivalent was calculated for each participant from Baseline to Month 6 and expressed as a number of months. Positive scores indicate increases in the age equivalent of the participant's social communication skills over time and are considered an improvement. Negative scores indicate decreases in the age equivalent of the participant's social communication skills and are considered worsening, and zero indicates no change. | Baseline, 6 months |
| Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Composite Standard Score (Parent Questionnaire) | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The PDD-BI assesses both social impairments and development of pro-social skills that are integral to improved reciprocal social behavior. The PDD-BI renders T scores (mean=50, standard deviation=10) based on comparisons to a standardized ASD population. The Autism Composite T score ranges from 10-100. The typical child with autism scores between 40-60.Higher scores indicate more severe autism symptoms and lower scores reflect milder symptoms. Change in this score from Baseline to Month 6 was calculated for each participant. Negative change scores indicate improvement in autism symptoms over time whereas positive scores indicate worsening of symptoms, and zero indicates no change in symptoms. | Baseline, 6 months |
| Change in Clinical Global Impressions - Severity of Illness (CGI-S) Score, Clinician Assessment | The CGI-S is a 7 point scale completed at the baseline and 6-month visits that requires the clinician to rate the severity of the participant's symptoms of autism at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. There are 3 CGI-S scores: the Social Communication Score, the Restricted and Repetitive Behaviors Score, and the Overall Score. The clinician's rates the severity of autism symptoms - 1, normal, no symptoms; 2, borderline level of symptoms; 3, mild symptoms; 4, moderate symptoms; 5, marked symptoms; 6, severe symptoms; or 7, extremely severe symptoms. Increases in the change score represent increases in symptom severity, decreases in the change score indicate improvement, and zero indicates no change. | Baseline, 6 months |
| Clinical Global Impressions - Global Improvement (CGI-I) Score, Clinician Assessment | The CGI-I is a 7 point scale that requires the clinician to assess how much the participant's autism symptoms have improved or worsened relative to a baseline assessment. The symptoms are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. There are three separate CGI-I ratings: social communicative functioning, restricted/repetitive interests and behaviors, and overall improvement. | Baseline, 6 months |
| Change in Expressive One-Word Picture Vocabulary Test (Clinician Assessment) | This Expressive One-Word Picture Vocabulary Test is a standardized evaluation of the child's expressive one-word vocabulary by a trained clinician. It tests an individual's ability to name, with one word, objects, actions, and concepts when presented with color illustrations. Higher EOWPVT standard scores reflect a better vocabulary. The minimum score is age-dependent (years:months) as follows. For a child age 2:0 to 2:1 the minimum is 65; age 2:2-2:3 (min=62); age 2:4-2:5 (min=60); age 2:6-2:7 (min=58); age 2:8-2:9 (min=57); age 2:10-2:11 (min=56); age 3:0 and older (min=55). The maximum possible score across all ages is 145. The change in score from Baseline to Month 6 was the outcome measure. Increases reflect increases in vocabulary skills, decreasing reflect decreases in vocabulary skills, and zero reflects no change. | Baseline, 6 months |
| Change in Vineland Adaptive Behavior Scales II (VABS-II) Communication Subscale Standard Score | The VABS-II measures adaptive functioning in socialization, communication, daily living, and motor skills. The Communication subscale standard score is derived by summing norm-referenced (by age group and sex) v-scale scores (mean=15, standard deviation=3) from the Receptive, Expressive, and Written communication subdomains and standardizing this sum to a normal distribution with mean=100 and standard deviation=15. Changes in the Communication standard score are indicative of skill acquisition relative to chronologically aged peers of the same sex. Thus, a zero (no change) represents change consistent with what is expected. An increase represents acquisition of more skills over time than would be expected. Participants who experience a decrease in Communication standard score may still have acquired skills although not at the rate expected based on their age and sex. | Baseline, 6 months |
| Change in Vineland Adaptive Behavior Scales II (VABS-II) Daily Living Subscale Standard Score | The VABS-II measures adaptive functioning in socialization, communication, daily living, and motor skills. The Daily Living standard score is derived by summing norm-referenced (by age group and sex) v-scale scores (mean=15, standard deviation=3) from the Personal, Domestic and Community subdomains and standardizing this sum to a normal distribution with mean=100 and standard deviation=15. Changes in the Daily Living standard score are indicative of skill acquisition relative to chronologically aged peers of the same sex. Thus, a zero (no change) represents change consistent with what is expected. An increase represents acquisition of more skills over time than would be expected. Participants who experience a decrease in Daily Living standard score may still have acquired skills although not at the rate expected based on their age and sex. | Baseline, 6 months |
| Change in Vineland Adaptive Behavior Scales II (VABS-II) Composite Score | The Vineland Adaptive Behavior Scales II (VABS-II) measures adaptive functioning in socialization, communication, daily living, and motor skills. The Adaptive Behavior Composite provides an overall summary of adaptive behavior across all of the domains. Each participant's score is standardized to a normal distribution with mean=100 and standard deviation=15. Positive scores indicate an increase in the Adaptive Behavior Composite Score over time whereas negative scores indicate decrease in the Adaptive Behavior Composite Score, and zero indicates no change in the Adaptive Behavior Composite Score. | Baseline, 6 months |
| Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Repetitive, Ritualistic and Pragmatic Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Repetitive, Ritualistic and Pragmatic Problems T-Score (mean=50, standard deviation=10) measures a broad range of behavioral problems associated with autism. The score ranges from 26-100 in patients aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Approach/Withdrawal Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Approach/Withdrawal Problems T-Score (mean=50, standard deviation=10) measures a broad range of behavioral problems associated with autism. The score ranges from 27-100 in patients aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Sensory/Perceptual Approach Behaviors T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Sensory/Perceptual Approach Behaviors T-score (mean=50, standard deviation=10) includes behaviors that are largely non-communicative and involve approach toward asocial stimuli. The score ranges from 31 to 86 in patients aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Ritualisms/Resistance to Change T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Ritualisms/Resistance to Change T-Score (mean=50, standard deviation=10) describes behaviors that communicate the child's desires to carry out rituals or to communicate dissatisfaction with a change in the environment or routine. The score ranges from 34 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Social Pragmatic Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Social Pragmatic Problems T-Score (mean=50, standard deviation=10) measures the difficulties children with autism have in either reacting to the approaches of others, understanding social conventions, or initiating social interactions with others. The score ranges from 29 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Semantic/Pragmatic Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Semantic/Pragmatic Problems T-Score (mean=50, standard deviation=10) assesses the difficulties children with autism have in using spoken language to indicate comprehension, communicate meaning, respond to the interests of others, and sustain a conversation. The score ranges from 34 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Arousal Regulation Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Arousal Regulation Problems T-Score (mean=50, standard deviation=10) measures behaviors that are largely non-communicative or unresponsive and reflect emotional constriction, the apparent seeking of kinesthetic sensation, and, in the parent version, difficulty with sleep regulation. The score ranges from 26 to 77 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Specific Fears T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Specific Fears T-Score (mean=50, standard deviation=10) measures behaviors that communicate the fears and anxieties associated with withdrawal from social or asocial stimuli. The score ranges from 36 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Aggressiveness T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Aggressiveness T-Score (mean=50, standard deviation=10) assesses the aggressive approach toward self or others, as well as the negative mood changes that are often associated with such behaviors. The score ranges from 36 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Expressive Social Communication Abilities T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Expressive Social Communication Abilities T-Score (mean=50, standard deviation=10) measures a broad range of social communication skills affected by autism. The score ranges from 20 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Receptive/Expressive Social Communication Ability T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Receptive/Expressive Social Communication Ability T-Score (mean=50, standard deviation=10) measures a broad range of social communication skills affected by autism. The score ranges from 20 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Social Approach Behaviors T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Social Approach Behaviors T-Score (mean=50, standard deviation=10) assesses those social communication skills that are notoriously difficult for children with autism (e.g., eye contact, joint attention, effective use of gesture, imaginative skills). The score ranges from 14 to 93 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Expressive Language T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Expressive Language T-Score (mean=50, standard deviation=10) assesses the ability of the child to speak the sounds associated with the English language and to use words and sentences that indicate his or her competence with grammar, tone of voice, and the pragmatic aspects of communicating with others. The score ranges from 28 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Baseline, Month 6 |
| Change in PDD-BI Learning, Memory, and Receptive Language T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Learning, Memory, and Receptive Language T-Score (mean=50, standard deviation=10) assesses two areas of variable competence in children with autism: (a) memory and (b) receptive language. The score ranges from 22 to 88 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Baseline, Month 6 |
| Number of Participants With Infusion Reactions | 12 months |
| Severity of Infusion Reactions | Grade/severity will be assessed according to CTCAE v4.0 guidelines | 12 months |
| Number of Participants With Product-related Infections | 12 months |
| Severity of Product-related Infections | Grade/severity will be assessed according to CTCAE v4.0 guidelines | 12 months |
| Evidence of Alloimmunization Via Anti-HLA (Human Leukocyte Antigen) and Anti-RBC (Red Blood Cell) Antibodies and Nonspecific Markers of Systemic Inflammation (ESR, CRP) | 12 months |
| Incidence of Graft vs. Host Disease | 12 months |
| Severity of Graft vs. Host Disease | Grade/severity will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 guidelines. | 12 months |
| Incidence of Unexpected Adverse Events, by Relation to Study Product | 6 months,12 months |
| Severity of Unexpected Adverse Events, by Relation to Study Product | Grade/severity will be assessed according to CTCAE v4.0 guidelines | 6 months, 12 months |
| Simhal AK, Carpenter KLH, Kurtzberg J, Song A, Tannenbaum A, Zhang L, Sapiro G, Dawson G. Changes in the geometry and robustness of diffusion tensor imaging networks: Secondary analysis from a randomized controlled trial of young autistic children receiving an umbilical cord blood infusion. Front Psychiatry. 2022 Oct 20;13:1026279. doi: 10.3389/fpsyt.2022.1026279. eCollection 2022. |
| BG001 |
| Placebo Infusion, Then Cord Blood Infusion |
Subjects will be randomized to receive a placebo infusion at the baseline visit, followed by a cord blood infusion at 6 months. The placebo is an acellular media product similar in both appearance and odor. The cord blood will be autologous (if available) or unrelated cord blood. Cord Blood Infusion Placebo |
| BG002 | Total | Total of all reporting groups |
| years |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Ethnicity (NIH/OMB) | Count of Participants | Participants |
|
| Race/Ethnicity, Customized | Count of Participants | Participants |
|
| Region of Enrollment | Count of Participants | Participants |
|
| ID |
|---|
| Title |
|---|
| Description |
|---|
| OG000 | Cord Blood Infusion - 6 Months | Subjects will be randomized to receive a cord blood infusion at the baseline visit. The cord blood will be autologous (if available) or unrelated cord blood. Cord Blood Infusion |
| OG001 | Placebo Infusion - 6 Months | Subjects will be randomized to receive a placebo infusion at the baseline visit. The placebo is an acellular media product similar in both appearance and odor. Placebo |
|
|
|
| Secondary | Change in Vineland Socialization Domain Raw Score | There are 3 raw scores within the Socialization domain of the VABS-3. These are the Interpersonal Relationships Raw Score (range: 0-86), the Play and Leisure Raw Score (range: 0-72), and the Coping Skills Raw Score (range: 0-66). Higher numbers on all three scores reflect better functioning in each area. Each raw score is the sum of the item scores in the respective subdomain of Socialization skills. The items are scored as follows: 2=usually present, 1=sometimes present, 0= never present. The item scores are assigned by a trained interviewer who interviews the parent of the child participating in the study. The change in raw score was calculated for each participant from Baseline to Month 6. Positive scores indicate improvement over time whereas negative scores indicate worsening, and zero indicates no change. The scores are not norm-referenced. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Change in Vineland Socialization Domain Age Equivalent | There are 3 age equivalent scores within the Socialization domain of the VABS-3: the Interpersonal Relationships Age Equivalent, the Play and Leisure Age Equivalent, and the Coping Sills Age Equivalent. An individual participant's age equivalent represents the chronological age (in years:months) at which their score would be considered normative. The age equivalent ranges are 0:0-22:0, 0:0-20:0, and 2:0-22:0 for the Interpersonal Relationships, Play and Leisure and Coping Skills age equivalents, respectively. The change in this age equivalent was calculated for each participant from Baseline to Month 6 and expressed as a number of months. Positive scores indicate increases in the age equivalent of the participant's social communication skills over time and are considered an improvement. Negative scores indicate decreases in the age equivalent of the participant's social communication skills and are considered worsening, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | months | Baseline, 6 months |
|
|
|
| Secondary | Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Composite Standard Score (Parent Questionnaire) | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The PDD-BI assesses both social impairments and development of pro-social skills that are integral to improved reciprocal social behavior. The PDD-BI renders T scores (mean=50, standard deviation=10) based on comparisons to a standardized ASD population. The Autism Composite T score ranges from 10-100. The typical child with autism scores between 40-60.Higher scores indicate more severe autism symptoms and lower scores reflect milder symptoms. Change in this score from Baseline to Month 6 was calculated for each participant. Negative change scores indicate improvement in autism symptoms over time whereas positive scores indicate worsening of symptoms, and zero indicates no change in symptoms. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Change in Clinical Global Impressions - Severity of Illness (CGI-S) Score, Clinician Assessment | The CGI-S is a 7 point scale completed at the baseline and 6-month visits that requires the clinician to rate the severity of the participant's symptoms of autism at the time of assessment, relative to the clinician's past experience with participants who have the same diagnosis. There are 3 CGI-S scores: the Social Communication Score, the Restricted and Repetitive Behaviors Score, and the Overall Score. The clinician's rates the severity of autism symptoms - 1, normal, no symptoms; 2, borderline level of symptoms; 3, mild symptoms; 4, moderate symptoms; 5, marked symptoms; 6, severe symptoms; or 7, extremely severe symptoms. Increases in the change score represent increases in symptom severity, decreases in the change score indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. Two additional subjects were excluded from the Cord Blood group because they were missing assessments. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Clinical Global Impressions - Global Improvement (CGI-I) Score, Clinician Assessment | The CGI-I is a 7 point scale that requires the clinician to assess how much the participant's autism symptoms have improved or worsened relative to a baseline assessment. The symptoms are rated as: 1, very much improved; 2, much improved; 3, minimally improved; 4, no change; 5, minimally worse; 6, much worse; or 7, very much worse. There are three separate CGI-I ratings: social communicative functioning, restricted/repetitive interests and behaviors, and overall improvement. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. Two additional subjects were excluded from the Cord Blood group because they were missing assessments. | Posted | Count of Participants | Participants | Baseline, 6 months |
|
|
|
| Secondary | Change in Expressive One-Word Picture Vocabulary Test (Clinician Assessment) | This Expressive One-Word Picture Vocabulary Test is a standardized evaluation of the child's expressive one-word vocabulary by a trained clinician. It tests an individual's ability to name, with one word, objects, actions, and concepts when presented with color illustrations. Higher EOWPVT standard scores reflect a better vocabulary. The minimum score is age-dependent (years:months) as follows. For a child age 2:0 to 2:1 the minimum is 65; age 2:2-2:3 (min=62); age 2:4-2:5 (min=60); age 2:6-2:7 (min=58); age 2:8-2:9 (min=57); age 2:10-2:11 (min=56); age 3:0 and older (min=55). The maximum possible score across all ages is 145. The change in score from Baseline to Month 6 was the outcome measure. Increases reflect increases in vocabulary skills, decreasing reflect decreases in vocabulary skills, and zero reflects no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. Three additional subjects were excluded from the Cord Blood group because they were missing assessments. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Change in Vineland Adaptive Behavior Scales II (VABS-II) Communication Subscale Standard Score | The VABS-II measures adaptive functioning in socialization, communication, daily living, and motor skills. The Communication subscale standard score is derived by summing norm-referenced (by age group and sex) v-scale scores (mean=15, standard deviation=3) from the Receptive, Expressive, and Written communication subdomains and standardizing this sum to a normal distribution with mean=100 and standard deviation=15. Changes in the Communication standard score are indicative of skill acquisition relative to chronologically aged peers of the same sex. Thus, a zero (no change) represents change consistent with what is expected. An increase represents acquisition of more skills over time than would be expected. Participants who experience a decrease in Communication standard score may still have acquired skills although not at the rate expected based on their age and sex. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Change in Vineland Adaptive Behavior Scales II (VABS-II) Daily Living Subscale Standard Score | The VABS-II measures adaptive functioning in socialization, communication, daily living, and motor skills. The Daily Living standard score is derived by summing norm-referenced (by age group and sex) v-scale scores (mean=15, standard deviation=3) from the Personal, Domestic and Community subdomains and standardizing this sum to a normal distribution with mean=100 and standard deviation=15. Changes in the Daily Living standard score are indicative of skill acquisition relative to chronologically aged peers of the same sex. Thus, a zero (no change) represents change consistent with what is expected. An increase represents acquisition of more skills over time than would be expected. Participants who experience a decrease in Daily Living standard score may still have acquired skills although not at the rate expected based on their age and sex. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Change in Vineland Adaptive Behavior Scales II (VABS-II) Composite Score | The Vineland Adaptive Behavior Scales II (VABS-II) measures adaptive functioning in socialization, communication, daily living, and motor skills. The Adaptive Behavior Composite provides an overall summary of adaptive behavior across all of the domains. Each participant's score is standardized to a normal distribution with mean=100 and standard deviation=15. Positive scores indicate an increase in the Adaptive Behavior Composite Score over time whereas negative scores indicate decrease in the Adaptive Behavior Composite Score, and zero indicates no change in the Adaptive Behavior Composite Score. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | score on a scale | Baseline, 6 months |
|
|
|
| Secondary | Change in Pervasive Developmental Disorder Behavior Inventory (PDD-BI) Repetitive, Ritualistic and Pragmatic Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Repetitive, Ritualistic and Pragmatic Problems T-Score (mean=50, standard deviation=10) measures a broad range of behavioral problems associated with autism. The score ranges from 26-100 in patients aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Approach/Withdrawal Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Approach/Withdrawal Problems T-Score (mean=50, standard deviation=10) measures a broad range of behavioral problems associated with autism. The score ranges from 27-100 in patients aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Sensory/Perceptual Approach Behaviors T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Sensory/Perceptual Approach Behaviors T-score (mean=50, standard deviation=10) includes behaviors that are largely non-communicative and involve approach toward asocial stimuli. The score ranges from 31 to 86 in patients aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Ritualisms/Resistance to Change T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Ritualisms/Resistance to Change T-Score (mean=50, standard deviation=10) describes behaviors that communicate the child's desires to carry out rituals or to communicate dissatisfaction with a change in the environment or routine. The score ranges from 34 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Social Pragmatic Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Social Pragmatic Problems T-Score (mean=50, standard deviation=10) measures the difficulties children with autism have in either reacting to the approaches of others, understanding social conventions, or initiating social interactions with others. The score ranges from 29 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Semantic/Pragmatic Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Semantic/Pragmatic Problems T-Score (mean=50, standard deviation=10) assesses the difficulties children with autism have in using spoken language to indicate comprehension, communicate meaning, respond to the interests of others, and sustain a conversation. The score ranges from 34 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Arousal Regulation Problems T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Arousal Regulation Problems T-Score (mean=50, standard deviation=10) measures behaviors that are largely non-communicative or unresponsive and reflect emotional constriction, the apparent seeking of kinesthetic sensation, and, in the parent version, difficulty with sleep regulation. The score ranges from 26 to 77 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Specific Fears T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Specific Fears T-Score (mean=50, standard deviation=10) measures behaviors that communicate the fears and anxieties associated with withdrawal from social or asocial stimuli. The score ranges from 36 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Aggressiveness T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Aggressiveness T-Score (mean=50, standard deviation=10) assesses the aggressive approach toward self or others, as well as the negative mood changes that are often associated with such behaviors. The score ranges from 36 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of severity. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect worsening of problem behaviors, decreases indicate improvement, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Expressive Social Communication Abilities T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Expressive Social Communication Abilities T-Score (mean=50, standard deviation=10) measures a broad range of social communication skills affected by autism. The score ranges from 20 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Receptive/Expressive Social Communication Ability T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Receptive/Expressive Social Communication Ability T-Score (mean=50, standard deviation=10) measures a broad range of social communication skills affected by autism. The score ranges from 20 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Social Approach Behaviors T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Social Approach Behaviors T-Score (mean=50, standard deviation=10) assesses those social communication skills that are notoriously difficult for children with autism (e.g., eye contact, joint attention, effective use of gesture, imaginative skills). The score ranges from 14 to 93 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Expressive Language T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Expressive Language T-Score (mean=50, standard deviation=10) assesses the ability of the child to speak the sounds associated with the English language and to use words and sentences that indicate his or her competence with grammar, tone of voice, and the pragmatic aspects of communicating with others. The score ranges from 28 to 100 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Change in PDD-BI Learning, Memory, and Receptive Language T-Score | The PDD-BI is an informant-based rating scale that assesses problem behaviors as well as appropriate social, language, and learning/memory skills. The Learning, Memory, and Receptive Language T-Score (mean=50, standard deviation=10) assesses two areas of variable competence in children with autism: (a) memory and (b) receptive language. The score ranges from 22 to 88 for participants aged 2-8 years. Higher values indicate increasing levels of competence. The change in this score from Baseline to Month 6 was calculated for each participant. Increases in the change score reflect improvement, decreases indicate worsening, and zero indicates no change. | Four subjects randomized to placebo were not included in the efficacy analyses. Two were pre-specified exclusions (defined as pilot subjects in the protocol) and two were found ineligible after enrollment. | Posted | Mean | Standard Deviation | T score | Baseline, Month 6 |
|
|
|
| Secondary | Number of Participants With Infusion Reactions | Posted | Count of Participants | Participants | 12 months |
|
|
|
| Secondary | Severity of Infusion Reactions | Grade/severity will be assessed according to CTCAE v4.0 guidelines | Posted | Count of Participants | Participants | 12 months |
|
|
|
| Secondary | Number of Participants With Product-related Infections | Posted | Count of Participants | Participants | 12 months |
|
|
|
| Secondary | Severity of Product-related Infections | Grade/severity will be assessed according to CTCAE v4.0 guidelines | There were no product-related infections in the study. | Posted | 12 months |
|
|
| Secondary | Evidence of Alloimmunization Via Anti-HLA (Human Leukocyte Antigen) and Anti-RBC (Red Blood Cell) Antibodies and Nonspecific Markers of Systemic Inflammation (ESR, CRP) | Posted | Count of Participants | Participants | 12 months |
|
|
|
| Secondary | Incidence of Graft vs. Host Disease | Posted | Count of Participants | Participants | 12 months |
|
|
|
| Secondary | Severity of Graft vs. Host Disease | Grade/severity will be assessed according to Common Terminology Criteria for Adverse Events (CTCAE) v4.0 guidelines. | There were no cases of graft vs. host disease in the study. | Posted | 12 months |
|
|
| Secondary | Incidence of Unexpected Adverse Events, by Relation to Study Product | Posted | Count of Participants | Participants | 6 months,12 months |
|
|
|
| Secondary | Severity of Unexpected Adverse Events, by Relation to Study Product | Grade/severity will be assessed according to CTCAE v4.0 guidelines | Posted | Count of Participants | Participants | 6 months, 12 months |
|
|
|
| 0 |
| 119 |
| 3 |
| 119 |
| 97 |
| 119 |
| EG001 | Placebo Infusion - 6 Months | Subjects will be randomized to receive a placebo infusion at the baseline visit. The placebo is an acellular media product similar in both appearance and odor. Placebo | 0 | 61 | 3 | 61 | 51 | 61 |
| EG002 | Cord Blood Infusion - 12 Months | Subjects will be randomized to receive a cord blood infusion at the baseline visit. The cord blood will be autologous (if available) or unrelated cord blood. Cord Blood Infusion | 0 | 61 | 3 | 61 | 41 | 61 |
| EG003 | Placebo Infusion - 12 Months | Subjects will be randomized to receive a placebo infusion at the baseline visit. The placebo is an acellular media product similar in both appearance and odor. Placebo | 0 | 119 | 2 | 119 | 83 | 119 |
| Dehydration | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Aggression | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Concussion | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Candida infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Infectious mononucleosis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Lung infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Molluscum contagiosum | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Otitis externa | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Tooth abscess | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Clavicle fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Epiphyseal fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Restless legs syndrome | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Bipolar disorder | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Distractibility | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Dysphemia | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Rhinorrhea | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Dermatitis diaper | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Adenoidectomy | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Ear tube removal | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Tonsillectomy | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Ear pain | Ear and labyrinth disorders | MedDRA | Non-systematic Assessment |
|
| Excessive eye blinking | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Eye pain | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Photophobia | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Strabismus | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Abdominal pain upper | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Anal incontinence | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Dental caries | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Diarrhea | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Dyspepsia | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Flatulence | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Food poisoning | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Frequent bowel movements | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Gastroesophageal reflux disease | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Nausea | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Toothache | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Fatigue | General disorders | MedDRA | Non-systematic Assessment |
|
| Influenza like illness | General disorders | MedDRA | Non-systematic Assessment |
|
| Pyrexia | General disorders | MedDRA | Non-systematic Assessment |
|
| Thirst | General disorders | MedDRA | Non-systematic Assessment |
|
| Food allergy | Immune system disorders | MedDRA | Non-systematic Assessment |
|
| Hypersensitivity | Immune system disorders | MedDRA | Non-systematic Assessment |
|
| Body tinea | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Conjunctivitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Croup infectious | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Ear infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Erythema infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Fungal infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Gastroenteritis viral | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Gastrointestinal infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Hand-foot-and-mouth disease | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Influenza | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Nasopharyngitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Otitis media | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Overgrowth fungal | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Pharyngitis Streptococcal | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Scarlet fever | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Sinusitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Streptococcal infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Upper respiratory tract infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Urinary tract infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Viral infection | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Allergic transfusion reaction | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Fall | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Infusion related reaction | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Blood urine present | Investigations | MedDRA | Non-systematic Assessment |
|
| Laboratory test abnormal | Investigations | MedDRA | Non-systematic Assessment |
|
| Vitamin D decreased | Investigations | MedDRA | Non-systematic Assessment |
|
| Appetite disorder | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Decreased appetite | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Joint laxity | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Muscle rigidity | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Toe walking | Musculoskeletal and connective tissue disorders | MedDRA | Non-systematic Assessment |
|
| Skin papilloma | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | MedDRA | Non-systematic Assessment |
|
| Disturbance in attention | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Headache | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Lethargy | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Poor quality sleep | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Psychomotor hyperactivity | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Repetitive speech | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Seizure | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Sensory processing disorder | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Somnolence | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Syncope | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Affect lability | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Aggression | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Agitation | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Anxiety | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Apathy | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Attention deficit/hyperactivity disorder | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Confusional state | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Defiant behavior | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Depressed mood | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Echolalia | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Encopresis | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Enuresis | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Food aversion | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Frustration tolerance decreased | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Impulsive behavior | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Insomnia | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Intentional self-injury | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Irritability | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Negativism | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infection | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Separation anxiety disorder | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Sleep disorder | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Social avoidant behavior | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Stereotypy | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Tic | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Eczema | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Pruritus | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Rash papular | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA | Non-systematic Assessment |
|
| Pallor | Vascular disorders | MedDRA | Non-systematic Assessment |
|
| Oral herpes | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Facial bones fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Wrist fracture | Injury, poisoning and procedural complications | MedDRA | Non-systematic Assessment |
|
| Streptococcus test positive | Investigations | MedDRA | Non-systematic Assessment |
|
| Sensory disturbance | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Aversion | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Restlessness | Psychiatric disorders | MedDRA | Non-systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Oropharyngeal pain | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Ear discomfort | Ear and labyrinth disorders | MedDRA | Non-systematic Assessment |
|
| Hypoacusis | Ear and labyrinth disorders | MedDRA | Non-systematic Assessment |
|
| Eye inflammation | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Visual impairment | Eye disorders | MedDRA | Non-systematic Assessment |
|
| Gastrointestinal dyskinetic disorders | Gastrointestinal disorders | MedDRA | Non-systematic Assessment |
|
| Drug hypersensitivity | Immune system disorders | MedDRA | Non-systematic Assessment |
|
| Bronchitis | Infections and infestations | MedDRA | Non-systematic Assessment |
|
| Cardiac murmur | Investigations | MedDRA | Non-systematic Assessment |
|
| Weight increased | Investigations | MedDRA | Non-systematic Assessment |
|
| Cow's milk intolerance | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Food refusal | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Gluten sensitivity | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Increased appetite | Metabolism and nutrition disorders | MedDRA | Non-systematic Assessment |
|
| Speech disorder | Nervous system disorders | MedDRA | Non-systematic Assessment |
|
| Nipple swelling | Reproductive system and breast disorders | MedDRA | Non-systematic Assessment |
|
| Nasal congestion | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Sinus congestion | Respiratory, thoracic and mediastinal disorders | MedDRA | Non-systematic Assessment |
|
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Dermatitis contact | Skin and subcutaneous tissue disorders | MedDRA | Non-systematic Assessment |
|
| Myringotomy | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Tooth repair | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
| Tooth extraction | Surgical and medical procedures | MedDRA | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| Coping Skills Raw Score |
|
| Coping Skills Age Equivalent Score |
|
| Overall Score |
|
| 3=Minimally Improved |
|
| 4=No Change |
|
| 5=Minimally Worse |
|
| 6=Much Worse |
|
| Restricted/repetitive Interests and Behaviors |
|
| Overall Score |
|
| Severe |
|
| Unrelated |
|
| Mild : Unrelated |
|
| Moderate : Related |
|
| Moderate : Unrelated |
|
| Severe : Related |
|
| Severe : Unrelated |
|